APUS net incomeQ2 2026-$20.17M
APUS net income was -$20.17M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$2.66M a year earlier. For the full fiscal 2025 it was -$6.00M, compared with -$1.39M in fiscal 2024.
Apimeds Pharmaceuticals US Inc. (APUS) financials
For the twelve months ended Jun 30, 2026, Apimeds Pharmaceuticals US Inc. reported -$58.17M of net income.
- Net income, TTM
- -$58.17M
- Free cash flow, TTM
- -$13.33M
- Cash
- $278.4K
- Total debt
- $5.00M
- Market cap
- $4.2M
FY2023FY2025
APUS revenue and earnings growth
APUS EPSQ2 2026-$11.77
APUS diluted EPS was -$11.77 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$5.50, compared with -$1.80 in fiscal 2024.
APUS free cash flowQ2 2026-$5.67M
APUS free cash flow was -$5.67M in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$8.98M.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Research and development | $1.63M | - | $98.5K |
| Selling, general and admin | $10.28M | $1.28M | $648.9K |
| Operating income | -$11.91M | -$1.28M | -$747.4K |
| Interest expense | $283.0K | $117.7K | $38.1K |
| Net income | -$6.00M | -$1.39M | -$777.7K |
| EPS, basic | -$5.50 | -$1.80 | -$1.70 |
| EPS, diluted | -$5.50 | -$1.80 | -$1.70 |
| Diluted shares | 1.1M | 790,385 | - |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Cash and equivalents | $1.64M | $3.5K | $410.5K |
| Short-term investments | $2.00M | - | - |
| Current assets | $13.98M | $13.1K | $422.1K |
| Total assets | $164.18M | $13.1K | $422.1K |
| Current liabilities | $10.71M | $1.02M | $123.3K |
| Long-term debt | - | $346.8K | - |
| Total debt | - | $346.8K | - |
| Total liabilities | $10.84M | $1.37M | $390.2K |
| Shareholders' equity | $153.35M | -$1.36M | $31.9K |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Operating cash flow | -$8.93M | -$733.5K | -$627.8K |
| Capital expenditures | $57.3K | - | - |
| Free cash flow | -$8.98M | - | - |
| Investing cash flow | -$10.06M | - | - |
| Financing cash flow | $20.62M | $326.5K | $1.03M |
| Stock-based compensation | $1.57M | - | $70.0K |
Key ratios
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $959.7K | $901.1K | $361.1K | $619.7K | $651.8K | $0 | - | - | - | - |
| Selling, general and admin | $5.32M | $11.28M | $6.68M | $1.22M | $2.01M | $364.4K | $275.6K | $300.0K | $427.8K | $271.7K |
| Operating income | -$6.28M | -$12.19M | -$7.04M | -$1.84M | -$2.66M | -$364.4K | -$275.6K | -$300.0K | -$427.8K | -$271.7K |
| Interest expense | $3.22M | $859.4K | $215.6K | $6.3K | $23.1K | $38.0K | $36.0K | $32.6K | $22.1K | $26.9K |
| Net income | -$20.17M | -$35.06M | -$1.16M | -$1.78M | -$2.66M | -$402.4K | -$311.6K | -$332.5K | -$449.4K | -$296.5K |
| EPS, basic | -$11.77 | -$22.60 | - | -$1.40 | -$2.57 | -$0.50 | -$0.40 | -$0.40 | -$0.60 | -$0.40 |
| EPS, diluted | -$11.77 | -$22.60 | - | -$1.40 | -$2.57 | -$0.50 | -$0.40 | -$0.40 | -$0.60 | -$0.40 |
| Diluted shares | 1.7M | 1.6M | - | 1.3M | 1.0M | 790,385 | - | 790,385 | 790,385 | 790,385 |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $278.4K | $979.5K | $1.64M | $6.99M | $8.74M | $250.4K | $3.5K | $26.6K | $63.3K | $147.4K |
| Short-term investments | - | $1.50M | $2.00M | - | - | - | - | - | - | - |
| Current assets | $10.68M | $13.15M | $13.98M | $9.09M | $10.35M | $259.9K | $13.1K | - | - | - |
| Total assets | $127.62M | $141.22M | $164.18M | $9.25M | $10.55M | $259.9K | $13.1K | - | - | - |
| Current liabilities | $21.07M | $14.58M | $10.71M | $1.09M | $809.0K | $1.77M | $1.02M | - | - | - |
| Long-term debt | - | - | - | - | - | - | $346.8K | - | - | - |
| Total debt | $5.00M | - | - | - | - | - | $346.8K | - | - | - |
| Total liabilities | $21.18M | $14.70M | $10.84M | $1.09M | $809.0K | $2.02M | $1.37M | - | - | - |
| Shareholders' equity | $106.45M | $126.52M | $153.35M | $8.16M | $9.74M | -$1.76M | -$1.36M | -$1.05M | -$714.0K | -$264.6K |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$5.67M | -$2.07M | -$3.82M | -$1.73M | -$3.36M | -$20.3K | -$99.6K | -$186.8K | -$184.1K | -$263.1K |
| Capital expenditures | $0 | $9.4K | $21.4K | $22.5K | - | - | - | - | - | - |
| Free cash flow | -$5.67M | -$2.08M | -$3.84M | -$1.75M | - | - | - | - | - | - |
| Investing cash flow | $1.50M | $490.6K | -$10.02M | -$22.5K | - | - | - | - | - | - |
| Financing cash flow | $3.47M | $920.0K | $8.49M | $0 | $11.86M | $267.2K | $76.5K | $150.0K | - | - |
| Stock-based compensation | - | - | $1.33M | $42.7K | - | - | - | - | - | - |
Key ratios
Source: XBRL data Apimeds Pharmaceuticals US Inc. files with the SEC, latest filing dated Aug 14, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-10, first reported Aug 14, 2026.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
APUS peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| APUS | - | - | -$58.17M | - | $4.2M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.27T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $664.95B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $514.92B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $361.71B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $310.17B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $289.10B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $190.39B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $178.51B |
APUS FAQ
5 questionsIs APUS profitable?
No. Apimeds Pharmaceuticals US Inc. reported a net loss of $58.17M for the twelve months ended Jun 30, 2026.How much cash and debt does APUS have?
Apimeds Pharmaceuticals US Inc. reported $278.4K in cash and cash equivalents and $5.00M of debt on its most recent balance sheet in SEC filings.What is APUS free cash flow?
Apimeds Pharmaceuticals US Inc. generated -$13.33M of free cash flow for the twelve months ended Jun 30, 2026, which is operating cash flow of -$13.28M less capital expenditures.When did APUS last report financial results?
The latest statements here come from Apimeds Pharmaceuticals US Inc.'s 10-Q filed on Aug 14, 2026, covering the period ended Jun 30, 2026.Where does this APUS financial data come from?
Quantisnow builds these statements from the structured XBRL data Apimeds Pharmaceuticals US Inc. files with the SEC. It is provided for information only and is not investment advice.